ADC Therapeutics secondary offering
We advised ADC Therapeutics on the registered secondary offering of its shares
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Roivant Sciences $230 million stock offering
We advised the company on its SEC-registered offering
TD SYNNEX $502 million secondary offering
The shares are listed on the NYSE
Pacific Biosciences $201.25 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Precigen $75 million follow-on offering
We advised Precigen on the SEC-registered offering
Deciphera Pharmaceuticals $135.1 million common stock offering
The common stock is listed on the Nasdaq Global Select Market
iQIYI $442 million follow-on offering
We advised the issuer on a follow-on offering of ADSs
New Horizon Health HK$781.7 million top-up placement of shares
We advised New Horizon Health on the top-up placement
Jinxin Fertility Group HK$1.17 billion top-up placement of shares
The shares are listed on the Hong Kong Stock Exchange
Expro $151.8 million secondary offering
The shares are listed on the NYSE